Cargando…
Ustekinumab for the treatment of refractory pediatric Crohn’s disease: a single-center experience
BACKGROUND/AIMS: Despite the well-established efficacy of tumor necrosis factor (TNF) antagonists as treatment options for Crohn’s disease, many pediatric patients need a change in therapy due to adverse events and loss of response, highlighting the necessity for medications with a different mechani...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Korean Association for the Study of Intestinal Diseases
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100375/ https://www.ncbi.nlm.nih.gov/pubmed/32312033 http://dx.doi.org/10.5217/ir.2019.09164 |